Literature DB >> 2443073

Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone.

B T Hyman, G W Van Hoesen, A R Damasio.   

Abstract

The perforant pathway is the primary source of cortical input to the hippocampal formation. Its cells of origin, in the entorhinal cortex, are destroyed in Alzheimer's disease. Because the principal neurotransmitter of the perforant pathway's excitatory action is thought to be glutamate, we microdissected a portion of the pathway's terminal zone and assayed the excised tissue for glutamate. There was an 83% decrease in the level of free glutamate in subjects with Alzheimer's disease as compared to control subjects not affected by dementia (p less than 0.005). We believe that this diminution in the glutamate content is a direct neurochemical correlate of perforant pathway destruction and that disruption of this crucial corticolimbic pathway contributes to the memory dysfunction in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443073     DOI: 10.1002/ana.410220110

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

1.  Neuronal inputs to hippocampal formation in Alzheimer's disease and in parkinsonism-dementia complex on Guam.

Authors:  S Goto; A Hirano
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 2.  Hippocampal plasticity during the progression of Alzheimer's disease.

Authors:  E J Mufson; L Mahady; D Waters; S E Counts; S E Perez; S T DeKosky; S D Ginsberg; M D Ikonomovic; S W Scheff; L I Binder
Journal:  Neuroscience       Date:  2015-03-12       Impact factor: 3.590

3.  Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory.

Authors:  Thomas van Groen; Pasi Miettinen; Inga Kadish
Journal:  Future Neurol       Date:  2014-01-01

4.  Effects of chronic inhalation of electronic cigarettes containing nicotine on glial glutamate transporters and α-7 nicotinic acetylcholine receptor in female CD-1 mice.

Authors:  Fawaz Alasmari; Laura E Crotty Alexander; Jessica A Nelson; Isaac T Schiefer; Ellen Breen; Christopher A Drummond; Youssef Sari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-03-27       Impact factor: 5.067

Review 5.  Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability.

Authors:  Giovanni Pennisi; Raffaele Ferri; Giuseppe Lanza; Mariagiovanna Cantone; Manuela Pennisi; Valentina Puglisi; Giulia Malaguarnera; Rita Bella
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

Review 6.  Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Neurochem Int       Date:  2017-02-20       Impact factor: 3.921

7.  Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease.

Authors:  A Solodkin; S D Veldhuizen; G W Van Hoesen
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

8.  Imaging cerebral 2-ketoisocaproate metabolism with hyperpolarized (13)C magnetic resonance spectroscopic imaging.

Authors:  Sadia A Butt; Lise V Søgaard; Peter O Magnusson; Mette H Lauritzen; Christoffer Laustsen; Per Åkeson; Jan H Ardenkjær-Larsen
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-28       Impact factor: 6.200

9.  Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors.

Authors:  R K Lee; R J Wurtman; A J Cox; R M Nitsch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 10.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.